CLB
Core Laboratories NV
10.50$
-1.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.2% | 15.2% | 4.3% | 13.1% | 9.7% | 16.0% | 5.4% | 10.7% | 6.3% | 5.7% | 3.3% | 6.3% | 5.4% | |
| 3.1% | 3.0% | 3.0% | 2.9% | 2.7% | 2.8% | 3.0% | 2.8% | 2.7% | 2.7% | 3.1% | 3.1% | 2.9% | |
| 1.7% | 1.2% | 3.7% | -0.1% | -1.4% | -0.4% | 3.4% | 0.4% | 1.0% | 0.8% | 4.1% | 0.7% | 1.6% | |
| 3.4% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -11.2% | 7.3% | -7.6% | 6.5% | -0.7% | 7.5% | -2.0% | 1.5% | -3.6% | -6.6% | -0.6% | -4.1% | -3.8% | |
| 2.8% | 2.0% | 2.4% | 2.2% | 2.0% | 3.4% | 2.9% | 3.3% | 2.3% | 2.7% | 4.0% | 4.6% | 3.4% | |
| -2.7% | -1.9% | -1.3% | -0.5% | -0.4% | -2.8% | 0.6% | -1.3% | 1.8% | -2.7% | -2.8% | -3.2% | -1.7% | |
| 0.4% | 0.4% | 0.4% | 0.4% | 0.3% | 0.4% | 0.4% | 0.4% | 0.3% | 0.3% | 0.4% | 0.4% | 0.4% | |
| -0.2% | -1.4% | 0.0% | -0.1% | -0.1% | -3.8% | -1.6% | -2.1% | -3.7% | -1.9% | -3.3% | -2.2% | -2.8% | |
| -3.2% | – | – | – | -6.0% | -10.8% | -1.6% | 0.0% | -6.7% | -2.9% | 3.3% | -0.5% | -1.9% | |
| -4.8% | -14.4% | -3.1% | -10.5% | -6.6% | -15.0% | -3.6% | -2.5% | -12.2% | -5.2% | -0.4% | -3.2% | -5.4% | |
| -7.6% | -1.2% | -0.2% | 2.1% | 2.8% | -1.8% | 2.4% | 7.0% | -4.1% | -2.1% | 0.1% | -0.1% | -1.6% | |
| -2.9% | 13.1% | 1.9% | 10.9% | 7.7% | 12.6% | 2.5% | 7.4% | 4.1% | 3.0% | -0.8% | 1.6% | 2.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.